Standard of care + chloroquine phosphate + telemedical approach.

COVID-19

Chloroquine phosphate

Telemedicine

Uniwersytecki Szpital Kliniczny

Wielospecjalistyczny Szpital Miejski

Chloroquine as Antiviral Treatment in Coronavirus Infection 2020

Multicenter, Randomized, Open-label, Non-commercial, Investigator-initiated Study to Evaluate the Efficacy and Safety of Chloroquine Phosphate in Combination With Telemedicine Care in the Risk Reduction of COVID-19 Related Hospitalization or Death, in Ambulatory Patients With COVID-19 Being at Risk of Serious Complications

Composite endpoint of COVID-19-related hospitalization or all-cause death

Decrease in self-reported symptoms of novel coronavirus infection. Non-dichotomous symptoms (e.g. syncope is dichotomous - yes or no) such as dyspnoea will be self-evaluated by patients using the 0-3 scale with the severity increasing with the punctation (0-no symptoms, 1-mild symptoms, 2-moderate symptoms, 3-severe symptoms).

Based on X-ray, microbiology and laboratory results

Acute respiratory distress syndrome, bacterial infection, shock, sepsis, etc

Wroclaw Medical University

Clopidogrel 75 mg/day plus cilostazol 100 mg twice/day

Ischemic Stroke

Peripheral Artery Disease

Diabetes Mellitus, Type 2

Clopidogrel

Cilostazol

Atherothrombosis Research Centre / Laboratory of Biochemistry, University of Ioannina

Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?

Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.

Death from vascular causes: cardiovascular or cerebrovascular

Blood disorders: thrombocytopenia, leukopenia, agranulocytosis, pancytopenia, aplastic anemia

quinoline/inflammation

Chloroquine as Antiviral Treatment in Coronavirus Infection 2020

Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen